Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (61-70 of 250) with videos related to

Pageof 25
Sort By:
Neurology and Therapy|March 24, 2025
Long-Term Management and Therapeutic Sequencing for Patients with Relapsing Multiple Sclerosis in France: A Vignette StudyPatrick Vermersch, Xavier Moisset, Baptiste Roux, et al.
Frontiers in Immunology|March 4, 2025
Artificial intelligence and science of patient input: a perspective from people with multiple sclerosisAnne Helme, Dipak Kalra, Giampaolo Brichetto, et al.
Immunology Letters|December 9, 2004
New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosisMohamed El Behi, Sylvain Dubucquoi, Didier Lefranc, et al.
Multiple Sclerosis and Related Disorders|January 27, 2020
Socioeconomic deprivation increases the risk of disability in multiple sclerosis patientsFloriane Calocer, Olivier Dejardin, Arnaud Kwiatkowski, et al.
Journal of Neurology|February 17, 2009
Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob diseaseHélène Zéphir, Tanya Stojkovic, Jérome de Seze, et al.
BMC Neurology|December 31, 2013
Extensive myelitis associated with anti-NMDA receptor antibodiesOlivier Outteryck, Guillaume Baille, Jérôme Hodel, et al.
Advances in Therapy|August 9, 2021
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension StudiesGavin Giovannoni, Giancarlo Comi, Kottil Rammohan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 25, 2024
Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis researchPer Soelberg Sørensen, Stephan Bramow, Melinda Magyari, et al.
European Cytokine Network|July 9, 2002
Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progressionLionel Almeras, Bertrand Meresse, Jérôme Seze, et al.
Clinical Neurology and Neurosurgery|January 12, 2010
Brain MRI findings in long-standing and disabling multiple sclerosis in 84 patientsDimitri Renard, Giovanni Castelnovo, Philippe-Jean Bousquet, et al.
Pageof 25

Showing results (61-70 of 250) with videos related to

Sort By:
Pageof 25
Neurology and Therapy|March 24, 2025
Long-Term Management and Therapeutic Sequencing for Patients with Relapsing Multiple Sclerosis in France: A Vignette StudyPatrick Vermersch, Xavier Moisset, Baptiste Roux, et al.
Frontiers in Immunology|March 4, 2025
Artificial intelligence and science of patient input: a perspective from people with multiple sclerosisAnne Helme, Dipak Kalra, Giampaolo Brichetto, et al.
Immunology Letters|December 9, 2004
New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosisMohamed El Behi, Sylvain Dubucquoi, Didier Lefranc, et al.
Multiple Sclerosis and Related Disorders|January 27, 2020
Socioeconomic deprivation increases the risk of disability in multiple sclerosis patientsFloriane Calocer, Olivier Dejardin, Arnaud Kwiatkowski, et al.
Journal of Neurology|February 17, 2009
Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob diseaseHélène Zéphir, Tanya Stojkovic, Jérome de Seze, et al.
BMC Neurology|December 31, 2013
Extensive myelitis associated with anti-NMDA receptor antibodiesOlivier Outteryck, Guillaume Baille, Jérôme Hodel, et al.
Advances in Therapy|August 9, 2021
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension StudiesGavin Giovannoni, Giancarlo Comi, Kottil Rammohan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 25, 2024
Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis researchPer Soelberg Sørensen, Stephan Bramow, Melinda Magyari, et al.
European Cytokine Network|July 9, 2002
Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progressionLionel Almeras, Bertrand Meresse, Jérôme Seze, et al.
Clinical Neurology and Neurosurgery|January 12, 2010
Brain MRI findings in long-standing and disabling multiple sclerosis in 84 patientsDimitri Renard, Giovanni Castelnovo, Philippe-Jean Bousquet, et al.
Pageof 25